Skip to main
  1. Stocks
  2. Curis
  3. Forecast
CRIS

Curis (CRIS) Stock Forecast & Price Target

Curis (CRIS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Curis is supported primarily by the strengthening registrational PCNSL data, where emavusertib plus ibrutinib delivered a 26% ORR across all 39 BTKi-experienced patients and 33% in 30 evaluable patients, while the BTKi-naïve cohort reached 86% ORR on an all-patients basis and 100% in five of five evaluable patients. The company also has a credible regulatory path, with prior FDA and EMA feedback supporting potential accelerated approval in the U.S. and Conditional Marketing Authorization in Europe, alongside management’s plan for full enrollment by 2027 and an NDA filing anticipated in 2028. Although Curis ended 3Q26 with only $5.0 million in cash, the subsequent $7.5 million private placement funds operations into 1Q27, and the expanding CLL program plus broader NHL optionality provide additional upside.

Bears say

Curis is facing a strained fundamental outlook because the increase in fully diluted share count after the October 2026 private placement and warrant repricing materially dilutes value, while management still needs substantial additional capital to fund development. Its lead PCNSL asset has shown only a 26% all-patients response rate in the BTKi-experienced cohort as of July 1, 2026, with a cohort that expanded 50% while the response rate held flat, and the more meaningful full-approval path now requires a randomized confirmatory study to be underway before filing. In addition, AML/MDS assumptions were weakened by lowering probability of success to 10% from 15% and pushing projected launch to 2033 from 2032, reinforcing concerns that clinical execution, financing needs, and dilution could pressure the stock.

Curis (CRIS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.

Curis (CRIS) Analyst Forecast & Price Prediction

Get the latest Curis (CRIS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Curis (CRIS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Curis (CRIS) Forecast

Analysts have given Curis (CRIS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Curis (CRIS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Curis (CRIS)


Curis (CRIS) Analyst Forecast & Price Prediction

Get the latest Curis (CRIS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Curis (CRIS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CRIS stock data and trends